Dossier assessment
Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Treatment of X-linked hypophosphataemia (XLH) in patients aged 1 to 17 years with radiographic evidence of bone disease
- Children aged 1 to 12 years with an RSS total score ≥ 2.0: added benefit not proven.
- Children aged 1 to 12 years with an RSS total score < 2.0: added benefit not proven.
- Adolescents aged 13 to 17 years: added benefit not proven.
Project details
- Project no.
- A22-11
- Commission
- Commission awarded on 01.03.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Children's and adolescents' health
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)
Status: Commission completed
-
Dossier assessment
Burosumab (X-linked hypophosphataemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V
Status: Commission completed
-
Dossier assessment
Burosumab (X-linked hypophosphataemia, = 18 years) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Burosumab (X-linked hypophosphataemia, 1 month to 1 year) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Burosumab (FGF23-related hypophosphataemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed